Wearable transportation device called The Chariot that is usable by amputees and those who experience difficulty standing up.
Exmovere Holdings has unveiled a wearable transportation device called, "The Chariot," that is usable by amputees and those who experience difficulty standing up.
The Chariot is a hands-free concept vehicle that is sensor-activated and was demonstrated at the company's McLean, Virginia headquarters. Unlike other self-balancing vehicles, The Exmovere Chariot is controlled by subtle movements of the person's lower torso and hips.
Sensors inside the cocoon-like shell of the vehicle predict the intended motion of the person wearing the device. The Chariot does not require any kind of manual dexterity on the part of the person wearing it. Only minimal physical effort is required, and The Chariot allows the person wearing it to reach objects and closely approach them. The upright form of The Chariot permits the person wearing it to make direct eye contact with other people. The device is battery powered and has the capability to travel up to twelve miles per hour.
David Bychkov, the CEO of Exmovere said, "The Chariot represents an exciting path for our company. Whereas our team was originally focused on designing sensor products that monitored signs of life, the Chariot's sensors are designed to make life more livable. We especially hope that the Chariot will offer dignity, strength and increased mobility to those who were wounded serving our country."
The Exmovere company is working on production versions of The Chariot in different forms, and intends to integrate their vital sign sensors, ground clearance and environmental sensors, wireless and cellular connectivity products, as well as a small form and unique options for both military and law enforcement customers. Exmovere, which means, 'emotion,' will also develop a feature of The Chariot that can switch the person wearing it from an upright position to a seated one. The company is seeking to partner with an automotive manufacturer in order to eventually launch a performance-oriented version of The Chariot.
Exmovere Holdings is a biomedical engineering company; they specialize in emotion-sensing applications for health care, mobility, and homeland security. The company's management team and directors are comprised of engineers and business professionals whose combined expertise exceeds one-hundred years in development of biomedical products, management of public companies, government service and commercial customers. David Bychkov, CEO and Cheyenne Crow, Director and COO have carried Exmovere technologies forward through seven years of intense research and development, different capital raises, as well as various product iterations. They are working to serve the company's growing base of shareholders as well as the public, which has an incredible appetite for vital sign monitoring products, chemical/biological hazard deterrents, as well as mobility devices.
The Exmovere Holdings company is currently working on two different branches of the health care sector. One of them involves remote patient monitoring, the other involves automated in-clinic triage. They are pursuing a joint strategy of developing new technologies while acquiring existing health care service businesses. The global telehealth market as a whole in America is expected to reach eight-billion dollars or more by the year 2012.
Exmovere controls the world's first and only Bluetooth bio-sensor wristwatch, which uses infrared sensors in order to detect a person's heart rate without the need for a chest strap. It has 3-d accelerometers to model human movement, and a variety of metallic sensors which detect the temperature of the person's skin and skin conductance. The wristwatch, now called the, 'Telepath,' transmits data through a computer or cell phone to online data centers, emergency services, or care givers. The Exmovere company, in a separate effort, also intends to launch a different bio-sensor wristwatch that will not only transmit data, but display and store it for lengthy periods of time as well. They intend to call it, 'The Empath, and it will benefit fitness users and persons who are cognitively able to monitor their own vital signs.
The company expects that with appropriate funding in place, its sales will represent approximately one-percent or eighty-million dollars by the end of 2014. Exmovere believes that as the market continues to exponentially grow, the Telepath, Empath and future wristwatch products will have a key role to play in consolidating services in the RPM sector. The company's goals related to urgent care clinics and RCM companies include collection of biomedical and market research data for validation of their wristwatch products, and development of new technologies to improve waiting room conditions, speed up triage, and provide medical professionals with an improved picture of the health of the people they are treating.